Equities analysts forecast that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will announce ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.06). Catalyst Pharmaceuticals posted earnings of ($0.05) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 40%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 8th.
On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.34) per share for the current fiscal year, with EPS estimates ranging from ($0.39) to ($0.25). For the next fiscal year, analysts forecast that the business will report earnings of ($0.08) per share, with EPS estimates ranging from ($0.12) to ($0.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06).
Several brokerages recently weighed in on CPRX. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. ValuEngine upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, May 14th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.25.
CPRX opened at $3.57 on Wednesday. Catalyst Pharmaceuticals has a one year low of $2.09 and a one year high of $4.51.
In other Catalyst Pharmaceuticals news, Director Donald A. Denkhaus acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were acquired at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director now directly owns 120,000 shares of the company’s stock, valued at approximately $450,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 49,000 shares of company stock worth $152,740 over the last 90 days. 9.60% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Securities LLC lifted its holdings in Catalyst Pharmaceuticals by 132.2% in the fourth quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 15,178 shares during the period. Tanaka Capital Management Inc. raised its holdings in Catalyst Pharmaceuticals by 6.4% in the fourth quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock worth $1,003,000 after purchasing an additional 15,515 shares during the period. California State Teachers Retirement System raised its holdings in Catalyst Pharmaceuticals by 18.2% in the first quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 20,484 shares during the period. New York State Common Retirement Fund raised its holdings in Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 24,200 shares during the period. Finally, Alps Advisors Inc. raised its holdings in Catalyst Pharmaceuticals by 23.6% in the first quarter. Alps Advisors Inc. now owns 137,441 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 26,262 shares during the period. Institutional investors and hedge funds own 53.33% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.